Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1982 Mar;79(5):1378–1382. doi: 10.1073/pnas.79.5.1378

Clonidine p-isothiocyanate, an affinity label for alpha 2-adrenergic receptors on human platelets.

D Atlas, M L Steer
PMCID: PMC345976  PMID: 6280179

Abstract

Exposure of intact human platelets or platelet membranes to the clonidine analog clonidine p-isothiocyanate (clonidine-NCS), followed by extensive washing, results in the loss of [3H]yohimbine binding to platelet alpha 2-receptors. In addition, exposure of intact platelets to clonidine-NCS, followed by extensive washing, results in the loss of of epinephrine-induced inhibition of adenylate cyclase activity [ATP pyrophosphate-lyase (cyclizing), EC 4.6.1.1] in frozen--thawed platelets and in purified platelet membranes. This effect is dependent on time and concentration (t 1/2 at 30 degrees C is less than 15 min; half-maximal effect occurs with clonidine-NCS at less than 10 microM). Clonidine-NCS appears to interact by irreversibly blocking the platelet alpha 2-receptors because (i) it abolishes alpha 2-receptor effects of adenylate cyclase activity (i.e., epinephrine-induced inhibition of basal and prostaglandin E1-stimulated activity) while not altering other cyclase activity (basal, prostaglandin E1-stimulated, and NaF-stimulated) and (ii) its effect on both [3H]yohimbine binding and epinephrine-induced inhibition of adenylate cyclase can be specifically prevented by alpha-agonists [(-)-epinephrine and clonidine] and alpha-antagonists (yohimbine and phentolamine). These observations indicate that clonidine-NCS is an effective affinity label for platelet alpha 2-receptors.

Full text

PDF
1378

Images in this article

1381Image
on p.1381

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ASTER R. H., JANDL J. H. PLATELET SEQUESTRATION IN MAN. II. IMMUNOLOGICAL AND CLINICAL STUDIES. J Clin Invest. 1964 May;43:856–869. doi: 10.1172/JCI104971. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Atlas D., Sabol S. L. Interaction of clonidine and clonidine analogues with alpha-adrenergic receptors of neuroblastoma X glioma hybrid cells and rat brain: comparison of ligand binding with inhibition of adenylate cyclase. Eur J Biochem. 1981 Jan;113(3):521–529. doi: 10.1111/j.1432-1033.1981.tb05094.x. [DOI] [PubMed] [Google Scholar]
  3. Berthelsen S., Pettinger W. A. A functional basis for classification of alpha-adrenergic receptors. Life Sci. 1977 Sep 1;21(5):595–606. doi: 10.1016/0024-3205(77)90066-2. [DOI] [PubMed] [Google Scholar]
  4. Cabantchik Z. I., Rothstein A. The nature of the membrane sites controlling anion permeability of human red blood cells as determined by studies with disulfonic stilbene derivatives. J Membr Biol. 1972 Dec 29;10(3):311–330. doi: 10.1007/BF01867863. [DOI] [PubMed] [Google Scholar]
  5. Cheng Y., Prusoff W. H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol. 1973 Dec 1;22(23):3099–3108. doi: 10.1016/0006-2952(73)90196-2. [DOI] [PubMed] [Google Scholar]
  6. Jakobs K. H., Saur W., Schultz G. Reduction of adenylate cyclase activity in lysates of human platelets by the alpha-adrenergic component of epinephrine. J Cyclic Nucleotide Res. 1976 Nov-Dec;2(6):381–392. [PubMed] [Google Scholar]
  7. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  8. Langer S. Z. Presynaptic regulation of catecholamine release. Biochem Pharmacol. 1974 Jul 1;23(13):1793–1800. doi: 10.1016/0006-2952(74)90187-7. [DOI] [PubMed] [Google Scholar]
  9. Moskowitz J., Harwood J. P., Reid W. D., Krishna G. The interaction of norepinephrine and prostaglandin E1 on the adenyl cyclase system of human and rabbit blood platelets. Biochim Biophys Acta. 1971 Feb 23;230(2):279–285. doi: 10.1016/0304-4165(71)90214-5. [DOI] [PubMed] [Google Scholar]
  10. Motulsky H. J., Shattil S. J., Insel P. A. Characterization of alpha 2-adrenergic receptors on human platelets using [3H]yohimbine. Biochem Biophys Res Commun. 1980 Dec 31;97(4):1562–1570. doi: 10.1016/s0006-291x(80)80044-1. [DOI] [PubMed] [Google Scholar]
  11. Mullins R. E., Langdon R. G. Maltosyl isothiocyanate: an affinity label for the glucose transporter of the human erythrocyte membrane. 1. Inhibition of glucose transport. Biochemistry. 1980 Mar 18;19(6):1199–1205. doi: 10.1021/bi00547a025. [DOI] [PubMed] [Google Scholar]
  12. Newman K. D., Williams L. T., Bishopric N. H., Lefkowitz R. J. Identification of alpha-adrenergic receptors in human platelets by [3H]dihydroergocryptine binding. J Clin Invest. 1978 Feb;61(2):395–402. doi: 10.1172/JCI108950. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Rouot B. R., Snyder S. H. [3H]Para-amino-clonidine: a novel ligand which binds with high affinity to alpha-adrenergic receptors. Life Sci. 1979 Aug 27;25(9):769–774. doi: 10.1016/0024-3205(79)90521-6. [DOI] [PubMed] [Google Scholar]
  14. Rouot B., Leclerc G., Bieth N., Wermuth C. G., Schwartz J. Etude pharmacologique de la para-aminoclonidine, sympathomimétique alpha. C R Acad Sci Hebd Seances Acad Sci D. 1978 Mar 20;286(11):909–912. [PubMed] [Google Scholar]
  15. Sabol S. L., Nirenberg M. Regulation of adenylate cyclase of neuroblastoma x glioma hybrid cells by alpha-adrenergic receptors. I. Inhibition of adenylate cyclase mediated by alpha receptors. J Biol Chem. 1979 Mar 25;254(6):1913–1920. [PubMed] [Google Scholar]
  16. Salomon Y., Londos C., Rodbell M. A highly sensitive adenylate cyclase assay. Anal Biochem. 1974 Apr;58(2):541–548. doi: 10.1016/0003-2697(74)90222-x. [DOI] [PubMed] [Google Scholar]
  17. Starke K. Regulation of noradrenaline release by presynaptic receptor systems. Rev Physiol Biochem Pharmacol. 1977;77:1–124. doi: 10.1007/BFb0050157. [DOI] [PubMed] [Google Scholar]
  18. Steer M. L., Khorana J., Galgoci B. Quantitation and characterization of human platelet alpha-adrenergic receptors using [3H]phentolamine. Mol Pharmacol. 1979 Nov;16(3):719–728. [PubMed] [Google Scholar]
  19. Steer M. L., Wood A. Regulation of human platelet adenylate cyclase by epinephrine, prostaglandin E1, and guanine nucleotides. Evidence for separate guanine nucleotide sites mediating stimulation and inhibition. J Biol Chem. 1979 Nov 10;254(21):10791–10797. [PubMed] [Google Scholar]
  20. Triner L., Vulliemoz Y., Verosky M., Nahas G. G. The effect of catecholamines on adenyl cyclase activity in rat uterus. Life Sci I. 1970 Jun 15;9(12):707–712. doi: 10.1016/0024-3205(70)90201-8. [DOI] [PubMed] [Google Scholar]
  21. Tsai B. S., Lefkowitz R. J. Agonist-specific effects of monovalent and divalent cations on adenylate cyclase-coupled alpha adrenergic receptors in rabbit platelets. Mol Pharmacol. 1978 Jul;14(4):540–548. [PubMed] [Google Scholar]
  22. U'Prichard D. C., Greenberg D. A., Snyder S. H. Binding characteristics of a radiolabeled agonist and antagonist at central nervous system alpha noradrenergic receptors. Mol Pharmacol. 1977 May;13(3):454–473. [PubMed] [Google Scholar]
  23. Wood C. L., Arnett C. D., Clarke W. R., Tsai B. S., Lefkowitz R. J. Subclassification of alpha-adrenergic receptors by direct binding studies. Biochem Pharmacol. 1979 Apr 15;28(8):1277–1282. doi: 10.1016/0006-2952(79)90424-6. [DOI] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES